US Physicians


The Sentinel Cerebral Protection System (CPS)

The Sentinel Cerebral Protection System captures and removes embolic debris in 99%* of TAVR patients, regardless of valve type. In the SENTINEL pivotal US IDE, peri-procedural stroke rate was reduced by 63%* when Sentinel CPS was used.

Sentinel is the protection your patients need when they’re most vulnerable.
Consider Protected TAVR™ with Sentinel CPS.


Protected TAVR patients had 63% fewer strokes, when compared to unprotected TAVR patients.1

The 63% reduction was confirmed in an independent real-world academic study from Ulm Germany which demonstrated a compelling 70% reduction in neurologist adjudicated TAVR Stroke, and Stroke or Mortality in the first 7-days post TAVR.

Click here to read a study in Journal of American College of Cardiology (JACC) that underscores how Sentinel CPS reduces TAVR 7-Day All-Stroke and 7-Day All-Stroke or All-Cause Mortality by 70%.2

2. Seeger J, et al. in press JACC 2017 SEPT

Click here to download a pdf of an overview of the Sentinel CPS clinical program. Safety and Efficacy of Protected Cardiac Intervention: Clinical Evidence for Sentinel Cerebral Embolic Protection, Ulrich Shäfer, Interventional Cardiology Review, Radcliffe Cardiology, Volume 12, Issue 2, Autumn 2017.

Click here to view how Sentinel is driving the largest compendium of clinical publications on Cerebral Embolic Protection.

Expert Insights & Evidence

Video – Claret Medical Scientific Symposium @ TCT 2017

Watch Claret Medical’s Scientific Symposium @ TCT 2017: Leadership in Protected TAVR with Sentinel as Standard of Care Chairs: Dr. Leon and Dr. Makkar. Faculty: Dr. Gada, Dr. Kapadia, Dr. Kodali, Dr. Messé, Dr. Siddiqui, Dr. Tchétché, Dr. Wöhrle

Video – Whiteboard Overview: University of Ulm Clinical Data on Sentinel® CPS

See an overview of how Sentinel® CPS reduced TAVR stroke, and stroke or mortality rates by 70%, in an independent, real-world, post-market academic study of 560 propensity matched patients from Ulm University (Seeger J. et al. in press JACC September 2017)

Video – Perspectives on 5,000th Patient with Sentinel CPS

Listen to perspectives from key opinion leaders on what it means that Claret Medical reached the 5,000th patient who used Sentinel™ Cerebral Embolic Protection.

Video – Dr. Marty Leon at FDA Advisory Committee Meeting

Watch Dr. Martin Leon’s powerful conclusion to the FDA advisory committee meeting, which summarizes the totality of the clinical evidence and resulted in a near unanimous Panel endorsement of Sentinel to protect American patients during TAVR.

Caution: Federal (USA) law restricts this device to sale by or on the order of a physician. Click here for the Indication, Contraindications, Warnings, and Precautions.